Chloroquine Suppresses the Development of Hypertension in Spontaneously Hypertensive Rats

American Journal of Hypertension

Volumn 30, Issue 2, 2017, Pages 173-181

  McCarthy, Cameron G ^a   Wenceslau, Camilla F ^a   Goulopoulou, Styliani ^c   Baban, Babak ^b   Matsumoto, Takayuki ^d   Webb, R Clinton ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b AUGUSTA UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^d HOSHI UNIVERSITY   (Japan)

Author keywords

blood pressure; hypertension; immune system; Toll like receptors

Indexed keywords

CHLOROQUINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOCHONDRIAL DNA; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; MYD88 PROTEIN, MOUSE; MYELOID DIFFERENTIATION FACTOR 88; TLR9 PROTEIN, MOUSE;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; CELL INFILTRATION; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; ESSENTIAL HYPERTENSION; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOBLOTTING; LYMPHOCYTE COUNT; LYSOSOME; MALE; NECROPTOSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SYSTOLIC BLOOD PRESSURE; T LYMPHOCYTE; THORACOTOMY; THYMECTOMY; UPREGULATION; VASCULARIZATION; WESTERN BLOTTING; ANIMAL; BLOOD PRESSURE; DISEASE EXACERBATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HYPERTENSION; IMMUNOLOGY; INNATE IMMUNITY; MESENTERIC ARTERY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR RESISTANCE; WISTAR KYOTO RAT;

ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; CHLOROQUINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HYPERTENSION; IMMUNITY, INNATE; MALE; MESENTERIC ARTERIES; MYELOID DIFFERENTIATION FACTOR 88; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TOLL-LIKE RECEPTOR 9; VASCULAR RESISTANCE;

EID: 85028951554     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/AJH/HPW113     Document Type: Article

References (40)

1. Singh MV, Chapleau MW, Harwani SC, Abboud FM. The immune system and hypertension. Immunol Res 2014; 59:243-253.
2. McCarthy CG, Goulopoulou S, Wenceslau CF, Spitler K, Matsumoto T, Webb RC. Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension. Am J Physiol Heart Circ Physiol 2014; 306:H184-H196.
3. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204:2449-2460.
4. Okuda T, Grollman A. Passive transfer of autoimmune induced hypertension in the rat by lymph node cells. Tex Rep Biol Med 1967; 25:257-264.
5. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008; 8:279-289.
6. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301-305.
7. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 2011; 108:1133-1145.
8. McCarthy CG, Wenceslau CF, Goulopoulou S, Ogbi S, Baban B, Sullivan JC, Matsumoto T, Webb RC. Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. Cardiovasc Res 2015; 107:119-130.
9. Stacey KJ, Young GR, Clark F, Sester DP, Roberts TL, Naik S, Sweet MJ, Hume DA. The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J Immunol 2003; 170:3614-3620.
10. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004; 5:190-198.
11. Ahmad-Nejad P, Häcker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002; 32:1958-1968.
12. Yi AK, Tuetken R, Redford T, Waldschmidt M, Kirsch J, Krieg AM. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol 1998; 160:4755-4761.
13. Häcker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, Heeg K, Lipford GB, Wagner H. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 1998; 17:6230-6240.
14. Bomfim GF, Dos Santos RA, Oliveira MA, Giachini FR, Akamine EH, Tostes RC, Fortes ZB, Webb RC, Carvalho MH. Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci (Lond) 2012; 122:535-543.
15. Long L, Yang X, Southwood M, Lu J, Marciniak SJ, Dunmore BJ, Morrell NW. Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation. Circ Res 2013; 112:1159-1170.
16. Baban B, Chandler PR, Johnson BA 3rd, Huang L, Li M, Sharpe ML, Francisco LM, Sharpe AH, Blazar BR, Munn DH, Mellor AL. Physiologic control of IDO competence in splenic dendritic cells. J Immunol 2011; 187:2329-2335.
17. Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, Mellor AL. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 2009; 183:2475-2483.
18. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186:4794-4804.
19. Gardner DL. Arteriolar necrosis and the prenecrotic phase of experimental hypertension. Q J Exp Physiol Cogn Med Sci 1963; 48:156-163.
20. Sagan L. On the origin of mitosing cells. J Theor Biol 1967; 14:255-274.
21. Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, Vandenabeele P. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 2011; 32:157-164.
22. Harwani SC, Chapleau MW, Legge KL, Ballas ZK, Abboud FM. Neurohormonal modulation of the innate immune system is proinflammatory in the prehypertensive spontaneously hypertensive rat, a genetic model of essential hypertension. Circ Res 2012; 111:1190-1197.
23. Brencicova E, Diebold SS. Nucleic acids and endosomal pattern recognition: how to tell friend from foe? Front Cell Infect Microbiol 2013; 3:37.
24. Singh MV, Cicha MZ, Meyerholz DK, Chapleau MW, Abboud FM. Dual activation of TRIF and MyD88 adaptor proteins by angiotensin II evokes opposing effects on pressure, cardiac hypertrophy, and inflammatory gene expression. Hypertension 2015; 66:647-656.
25. Bomfim GF, Echem C, Martins CB, Costa TJ, Sartoretto SM, Dos Santos RA, Oliveira MA, Akamine EH, Fortes ZB, Tostes RC, Webb RC, Carvalho MH. Toll-like receptor 4 inhibition reduces vascular inflammation in spontaneously hypertensive rats. Life Sci 2015; 122:1-7.
26. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 2011; 36:320-328.
27. Szasz T, Bomfim GF, Webb RC. The influence of perivascular adipose tissue on vascular homeostasis. Vasc Health Risk Manag 2013; 9:105-116.
28. Khraibi AA, Smith TL, Hutchins PM, Lynch CD, Dusseau JW. Thymectomy delays the development of hypertension in Okamoto spontaneously hypertensive rats. J Hypertens 1987; 5:537-541.
29. Crowley SD, Song YS, Lin EE, Griffiths R, Kim HS, Ruiz P. Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 2010; 298:R1089-R1097.
30. Marvar PJ, Thabet SR, Guzik TJ, Lob HE, McCann LA, Weyand C, Gordon FJ, Harrison DG. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ Res 2010; 107:263-270.
31. Okamoto E, Couse T, De Leon H, Vinten-Johansen J, Goodman RB, Scott NA, Wilcox JN. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation 2001; 104:2228-2235.
32. DeGrendele HC, Estess P, Picker LJ, Siegelman MH. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway. J Exp Med 1996; 183:1119-1130.
33. Huet S, Groux H, Caillou B, Valentin H, Prieur AM, Bernard A. CD44 contributes to T cell activation. J Immunol 1989; 143:798-801.
34. Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 2000; 95:3460-3466.
35. Xu JC, Peng YB, Wei MY, Wu YF, Guo D, Qin G, Ji G, Shen J, Liu QH. Chloroquine Inhibits Ca(2+) Signaling in Murine CD4(+) Thymocytes. Cell Physiol Biochem 2015; 36:133-140.
36. Mathis KW, Broome HJ, Ryan MJ. Autoimmunity: an underlying factor in the pathogenesis of hypertension. Curr Hypertens Rep 2014; 16:424.
37. Scherbel AL, Schuchter SL, Harrison JW. Comparison of effects of two antimalarial agents, hydroxychloroquine sulfate and chloroquine phosphate, in patients with rheumatoid arthitis. Cleve Clin Q 1957; 24:98-104.
38. Tye MJ, White H, Appel B, Ansell HB. Lupus erythematosus treated with a combination of quinacrine, hydroxychloroquine and chloroquine. N Engl J Med 1959; 260:63-66.
39. Wozniacka A, Carter A, McCauliffe DP. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 2002; 11:71-81.
40. Aranow C, Ginzler EM. Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 2000; 9:166-169.